1-<4-(chloromethyl)-2-hydroxy-3-propylphenyl>ethanone | 97582-36-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-<4-(chloromethyl)-2-hydroxy-3-propylphenyl>ethanone
• 英文别名: 4-acetyl-3-hydroxy-2-propylbenzyl chloride；1-[4-(chloromethyl)-2-hydroxy-3-propylphenyl]ethanone
• CAS: 97582-36-0
• 化学式: C₁₂H₁₅ClO₂
• 分子量: 226.703
• InChiKey: HQBJCQPAIQUMOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-<4-(chloromethyl)-2-hydroxy-3-propylphenyl>ethanone 在 三氯化铝 、 sodium ethanolate 、 sodium iodide 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 84.0h， 生成 6-[4-(4-Acetyl-3-hydroxy-2-propyl-benzyloxy)-phenyl]-6-oxo-hexanenitrile
  参考文献：
  名称：

  (Phenylmethoxy)phenyl derivatives of w-oxo- and w-tetrazolylalkanoic acids and related tetrazoles. Synthesis and evaluation as leukotriene D4 receptor antagonists

  摘要：

  Two series of (phenylmethoxy)phenyl compounds derived from the structure of LY163443 were synthesized and evaluated as leukotriene D4 receptor antagonists. In the OMEGA-[(phenylmethoxy)phenyl]-OMEGA-oxoalkanoic acid series, 5-[4-[(4-acetyl-2-ethyl-3-hydroxyphenyl)methoxy]phenyl]-3,3-dimethyl-5-oxopentanoic acid (8) was the most potent antagonist of LTD4-induced contractions of guinea pig ileum (pK(B) of 7.60) and LTD4 pressor response in pithed rats (ED50 of 1.4 mg/kg iv). Replacing the carboxylic acid function with 5-tetrazole gave slightly more potent compounds. In the OMEGA-[5-[[(phenylmethoxy)phenyl]alkyl]tetrazolyl]alkanoic acid series, replacing the carboxylic acid with 5-tetrazole gave compounds that were equally effective in the guinea pig ileum but more potent in vivo against the LTD4 pressor response in rat. The pK(B) value in the guinea pig ileum for 1-[2-hydroxy-3-propyl-4-[[4-[[2-[3-(1H-tetrazol-5-yl)propyl]-2H-tetrazol-5-yl]methyl]phenoxy]methyl]phenyl]ethanone (25) was 7.87 and the ED50 for antagonism of the LTD4 pressor response was 4.0 mg/kg iv. The sodium salts of 8 (9) and 25 (26) given by the iv route of administration antagonized LTD4-induced cardiovascular alterations in anesthetized rat and LTD4-induced bronchoconstriction in guinea pig in a dose-dependent manner. Oral activity was also demonstrated against the LTD4-induced bronchoconstriction in guinea pig.

  DOI：

  10.1021/jm00113a014
• 作为产物：
  描述：

  1-<4-<(dimethylamino)methyl>-2-hydroxy-3-propylphenyl>ethanone 在 氯甲酸乙酯 作用下， 以 甲苯 为溶剂， 反应 2.0h， 以68%的产率得到1-<4-(chloromethyl)-2-hydroxy-3-propylphenyl>ethanone
  参考文献：
  名称：

  白三烯受体拮抗剂。2。[[（四唑-5-基芳基）氧基]甲基]苯乙酮衍生物。

  摘要：

  合成了一系列[[（（四唑-5-基芳基）氧基]甲基]苯乙酮，并作为白三烯D4诱导的豚鼠回肠收缩的拮抗剂进行了评估。在苯乙酮的3-位上用乙基（66），丙基（68），丁基（83）和异丁基（84）取代，得到的-log IC 50值分别为7.9、8.0、7.8和7.7。当四唑-5-基通过化学键（67），亚甲基（68）或乙烯（71）与对位的第二个苯环连接时，会得到同样有效的化合物。为了保持高拮抗剂活性，苯乙酮应在2位上被羟基取代，四唑环应具有酸性氢原子。1- [2-羟基-3-丙基-4-[[4-（1H-四唑-5-基甲基）苯氧基]甲基]苯基]乙酮（68，

  DOI：

  10.1021/jm00388a028

文献信息

• Benzylidene rhodanines
  申请人：Eli Lilly and Company

  公开号：US05747517A1

  公开（公告）日：1998-05-05

  This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with .beta.-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.

  本发明提供了一种新型的苄亚胺硫代缩苹果酸，它们作为治疗或预防与β-淀粉样肽相关疾病的药物很有用。本发明还提供了治疗或预防阿尔茨海默病的方法，该方法包括向需要的哺乳动物施用有效量的本发明的一种或多种苄亚胺硫代缩苹果酸。
• Thiadizazole compounds as antagonists of SRS-A
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US04803211A1

  公开（公告）日：1989-02-07

  This invention relates to novel heterocyclic compounds structurally characterized by containing a specific heterocyclic group and by the presence of --CH.sub.2 --S-- directly bound to the specific heterocyclic group. These heterocyclic compounds are useful as medicines, particularly as antagonists of SRS-A (slow reacting substance of anaphylaxis).

  这项发明涉及一类新颖的杂环化合物，其结构特征在于含有特定的杂环基团，并且直接与特定的杂环基团相结合的是--CH.sub.2 --S--。这些杂环化合物可用作药物，特别是作为SRS-A（过敏性反应的缓慢反应物质）的拮抗剂。
• Leukotriene antagonist intermediates
  申请人：Eli Lilly and Company

  公开号：US05105017A1

  公开（公告）日：1992-04-14

  This invention provides novel benzene derivatives which are leukotriene antagonists, formulations of those derivatives, intermediates for preparing the derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.

  这项发明提供了新颖的苯乙烯衍生物，它们是白三烯拮抗剂，包括这些衍生物的配方、制备这些衍生物的中间体，以及使用这些衍生物治疗由白三烯过度释放引起的病症的方法。
• Leukotriene antagonists
  申请人：Eli Lilly and Company

  公开号：US04874777A1

  公开（公告）日：1989-10-17

  This invention provides benzene derivatives which are leukotriene antagonists, formulations of those derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.

  这项发明提供了苯基衍生物，这些衍生物是白三烯拮抗剂，以及这些衍生物的配方，以及使用这些衍生物治疗白三烯过度释放引起的疾病的方法。
• Leukotriene antagonists and use thereas
  申请人：Eli Lilly and Company

  公开号：US04853398A1

  公开（公告）日：1989-08-01

  This invention provides benzene derivatives which are leukotriene antagonists, formulations of those derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.

  这项发明提供了苯乙烯衍生物，这些衍生物是白三烯拮抗剂，以及这些衍生物的配方，以及使用这些衍生物治疗由白三烯过度释放引起的疾病的方法。